Last reviewed · How we verify
NCT07215988
Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
trial testing Non-Interventional Study in Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 in 70 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 4 February 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Non-Interventional Study (non-interventional-study) — full drug profile →
Conditions studied
- Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 — all drugs for Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 →
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 — all drugs for Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 →
- Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 — all drugs for Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 →
- Locally Advanced Basal Cell Carcinoma — all drugs for Locally Advanced Basal Cell Carcinoma →
Sponsor
Ohio State University Comprehensive Cancer Center
Who can join
18 and older, any sex, with Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 or Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the time spent on obtaining insurance approval and drugs, means of insurance coverage, out-of-pocket costs for patients, and the surgical outcomes after neoadjuvant treatment is completed in skin cancer patients receiving "off label" and "on label" neoadjuvant treatment. "Neoadjuvant therapy" means cancer treatment given before surgery. However, in many instances, neoadjuvant therapy is used as an "off-label" approach for several types of skin cancers. "Off-label" means that the FDA has not yet approved its use for that type of cancer. Therefore, insurance approval of these "off-label" treatments could be delayed compared to label use, and "off-label" treatments may require several weeks of pre-authorization. There is evidence that the delayed start of cancer treatment can lead to poorer outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07215988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional Study
Trials testing the same drug.
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT06607874 — Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in · not yet recruiting
- NCT06630338 — Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements · not yet recruiting
- NCT07235501 — Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato · not yet recruiting
Other Ohio State University Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
- NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07215988 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07215988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing